huIL18R1/huIL18RAP/huIL18BP Mouse
Product Name
huIL18R1/huIL18RAP/huIL18BP Mouse
Product ID
C002137
Strain Name
C57BL/6Cya-Il18r1tm1(hIL18R1)Il18raptm1(hIL18RAP)Il18bptm1(hIL18BP)/Cya
Background
C57BL/6Cya
Status
When using this mouse strain in a publication, please cite “huIL18R1/huIL18RAP/huIL18BP Mouse (Catalog C002137) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
Gene Name
IL18RAP & IL18R1
Gene Alias
ACPL, CD218b, IL-1R7, IL18RB, CDw218b, IL-1R-7, IL-18RAcP, IL-1RAcPL, IL-18Rbeta, IL-18R-beta, CD218a, IL18RA, IL1RRP, CDw218a, IL-1Rrp, IL-18Ralpha, IL18Ralpha2, IL-18R-alpha
NCBI ID
Chromosome
Chr 2 (Human), Chr 2 (Human)
MGI ID
Datasheet
Strain Description
Interleukin-18 (IL-18) is an important pro-inflammatory cytokine that binds to its receptor complex (IL-18Rα encoded by IL18R1 and IL-18Rβ encoded by IL18RAP), activating downstream MyD88/NF-κB and MAPK signaling pathways and playing key regulatory roles in innate and adaptive immunity [1]. The IL18BP (Interleukin 18 Binding Protein) gene encodes a secreted, high-affinity, naturally occurring antagonist of the proinflammatory cytokine IL-18, functioning by binding IL-18 to prevent it from interacting with its receptor, thereby inhibiting IL-18-induced immune responses, such as interferon-gamma (IFN-γ) production [2]. The gene's protein, IL-18BP, is constitutively expressed and secreted primarily by mononuclear cells (such as monocytes/macrophages and T-cells) and is widely expressed at the RNA level in numerous tissues, including the spleen, lung, placenta, and small intestine [3].
The huIL18R1/huIL18RAP/huIL18BP mouse is a triple-gene humanized model obtained by crossing the huIL18R1/huIL18RAP mouse (Catalog No.: C002016) with the huIL18BP mouse (Catalog No.: C001869). The huIL18R1/huIL18RAP/huIL18BP mouse can be utilized for screening, pharmacodynamic evaluation, safety assessment, and mechanism of action studies of multi-target therapeutics targeting the IL-18 receptor complex (IL18R1/IL18RAP) and the natural antagonist of IL-18, IL18BP. It provides an ideal preclinical research platform for developing innovative therapies for inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and systemic lupus erythematosus (SLE), as well as for tumor immunology-related research.
Reference
Zhao Y, Tang Y, Zhu X, Hou Y, Li H, Ciccia F, Zou H, Lu L. The Roles of Interleukin-18 in Inflammation and Autoimmune Disease. Clin Rev Allergy Immunol. 2026 Mar 16;69(1):17.
Park SY, Hisham Y, Shin HM, Yeom SC, Kim S. Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases. Biomedicines. 2022 Jul 20;10(7):1750.
Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013 Oct 8;4:289.
Strain Strategy
The huIL18R1/huIL18RAP/huIL18BP mouse is a humanized model obtained by crossing the huIL18R1/huIL18RAP mouse (Catalog No.: C002016) with the huIL18BP mouse (Catalog No.: C001869).
Figure 1. Gene editing strategy of huIL18R1/huIL18RAP mice. The sequence from exon 1 of the mouse Il18r1 gene to the downstream of exon 13 of the Il18rap gene was replaced with the sequence from exon 1 of the human IL18R1 gene to the downstream of exon 10 of the IL18RAP gene. Since the replaced human genomic fragment contains the SDR42E1P5 pseudogene and MIR4772 microRNA gene, these human genomic elements were also introduced into the mouse genome as part of the humanized region.
Figure 2. Gene editing strategy for huIL18BP mice. The sequences from the start codon to the stop codon of the endogenous mouse Il18bp gene were replaced with the sequences from the start codon to the stop codon of the human IL18BP gene.
Application Area
Multi-target drug screening, pharmacodynamic evaluation, safety evaluation, and mechanism-of-action research targeting the IL-18 receptor complex (IL18R1/IL18RAP) and IL18BP, the natural antagonist protein of IL-18;
Development of innovative therapies for inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, systemic lupus erythematosus (SLE), and tumor immunology-related research.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.